Many women experience depression during pregnancy. What is the best way to identify these women?
Some studies have demonstrated associations between in utero exposure to antidepressants and cognitive outcomes.
SSRI and SNRI antidepressants were not associated with an increased risk for gestational diabetes.
The reality is that most of the antidepressants taken by women today are relatively safe and carry a very low risk to the developing fetus.
While we have data to support the use of antidepressants, including the selective serotonin reuptake inhibitors (SSRIs) and the serotonin norepinephrine reuptake inhibitors (SNRIs), during pregnancy, most studies have focused on risk of congenital [...]
This is the first installment of a new feature on our website: ESSENTIAL READS This is a kind of shortcut which allows you to find the most relevant reviews and articles in reproductive psychiatry. [...]
While we have heard a lot about brexanolone, marketed by Sage Therapeutics as Zulresso, for the treatment of postpartum depression, an oral version of this novel antidepressant – SAGE 217 or zuranolone – has been [...]
Zuranolone or SAGE-217 is similar to brexanolone (marketed as Zulresso), the medication which was FDA-approved for the treatment of postpartum depression. Zuranolone is a neurosteroid, an analogue of allopregnanolone, which is a positive allosteric [...]
Women face difficult choices when deciding whether or not to continue psychiatric medications during pregnancy. For many years, we have typically recommended the older antidepressants, including the selective serotonin reuptake inhibitors or SSRIs such [...]
It has been a few months since Zulresso (brexanolone), the new FDA-approved treatment for postpartum depression, has been available. At our clinic, we have had multiple queries regarding how to obtain treatment with Zulresso. One [...]